Cart
sales@molnova.com
Emodin 8-O-(6-methylmalonyl)-glucopyranoside
CAS No. 928262-58-2
Emodin 8-O-(6-methylmalonyl)-glucopyranoside( ——— )
Catalog No. M38879 CAS No. 928262-58-2
Emoghrelin, isolated from Heshouwu Polygonum multiflorum, stimulates growth hormone secretion via activation of the ghrelin receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEmodin 8-O-(6-methylmalonyl)-glucopyranoside
-
NoteResearch use only, not for human use.
-
Brief DescriptionEmoghrelin, isolated from Heshouwu Polygonum multiflorum, stimulates growth hormone secretion via activation of the ghrelin receptor.
-
DescriptionEmoghrelin, isolated from Heshouwu Polygonum multiflorum, stimulates growth hormone secretion via activation of the ghrelin receptor.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number928262-58-2
-
Formula Weight518.42
-
Molecular FormulaC24H22O13
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Curculigoside B
Curculigoside B shows antioxidative and antiosteoporotic activities, it can decrease area of bone resorption pit, osteoclastic formation and TRAP activity.
-
SB290157 trifluoroac...
SB290157 trifluoroacetate is a potent and selective antagonist of C3a receptor(IC50 of 200 nM). SB 290157 is a competitive antagonist of 125I-C3a radioligand binding to rat basophilic leukemia-2H3 cells expressing the human C3aR (RBL-C3aR, IC50 of 200 nM).
-
Icosabutate
Icosabutate (NST-4016) is an orally active derivative of eicosapentaenoic acid that inhibits hepatic inflammation and fibrosis in NASH, improves cardiovascular risk profiles in statin-treated patients with residual hypertriglyceridemia, lowers triglycerides, and may be useful in studies of liver fibrosis and atherosclerosis.
